CN116917318A - 抗cd25抗体 - Google Patents

抗cd25抗体 Download PDF

Info

Publication number
CN116917318A
CN116917318A CN202180090876.8A CN202180090876A CN116917318A CN 116917318 A CN116917318 A CN 116917318A CN 202180090876 A CN202180090876 A CN 202180090876A CN 116917318 A CN116917318 A CN 116917318A
Authority
CN
China
Prior art keywords
seq
antibody
binding fragment
antigen
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180090876.8A
Other languages
English (en)
Chinese (zh)
Inventor
D·奥利芙
A·邦叙桑
J·朱斯蒂尼亚尼
A·马里耶-卡迪纳
阿尔诺·福萨特
J·胡阿辛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alderaan Biotechnology
Western Dais Paris, University of
Aix Marseille Universite
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Est Creteil Val de Marne
Institut Jean Paoli and Irene Calmettes
Original Assignee
Alderaan Biotechnology
Western Dais Paris, University of
Aix Marseille Universite
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Est Creteil Val de Marne
Institut Jean Paoli and Irene Calmettes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alderaan Biotechnology, Western Dais Paris, University of, Aix Marseille Universite, Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris Est Creteil Val de Marne, Institut Jean Paoli and Irene Calmettes filed Critical Alderaan Biotechnology
Publication of CN116917318A publication Critical patent/CN116917318A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180090876.8A 2020-11-20 2021-11-19 抗cd25抗体 Pending CN116917318A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20306424 2020-11-20
EP20306424.1 2020-11-20
PCT/EP2021/082383 WO2022106665A1 (en) 2020-11-20 2021-11-19 Anti-cd25 antibodies

Publications (1)

Publication Number Publication Date
CN116917318A true CN116917318A (zh) 2023-10-20

Family

ID=73698744

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180090876.8A Pending CN116917318A (zh) 2020-11-20 2021-11-19 抗cd25抗体

Country Status (9)

Country Link
US (1) US20240002522A1 (https=)
EP (1) EP4247497A1 (https=)
JP (1) JP2023550446A (https=)
KR (1) KR20230118108A (https=)
CN (1) CN116917318A (https=)
AR (1) AR124123A1 (https=)
AU (1) AU2021380966A1 (https=)
CA (1) CA3199006A1 (https=)
WO (1) WO2022106665A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023222886A1 (en) 2022-05-20 2023-11-23 Depth Charge Ltd Antibody-cytokine fusion proteins

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US61816A (en) 1867-02-05 bunbab and a
US96973A (en) 1869-11-16 saxton
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
PL2602323T3 (pl) 2007-06-01 2018-06-29 Open Monoclonal Technology, Inc. Kompozycje i sposoby hamowania endogennych genów immunoglobin i wytwarzania transgenicznych ludzkich przeciwciał typu idiotypowego
US11879014B2 (en) * 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
EP3649153B8 (en) * 2017-07-06 2025-07-16 Tusk Therapeutics Ltd Fc optimised anti-cd25 antibodies for tumor specific cell depletion
US10752691B2 (en) * 2018-03-13 2020-08-25 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
EP3972997A1 (en) * 2019-05-20 2022-03-30 Institut National de la Santé et de la Recherche Médicale (INSERM) Novel anti-cd25 antibodies

Also Published As

Publication number Publication date
CA3199006A1 (en) 2022-05-27
JP2023550446A (ja) 2023-12-01
EP4247497A1 (en) 2023-09-27
KR20230118108A (ko) 2023-08-10
US20240002522A1 (en) 2024-01-04
AU2021380966A1 (en) 2023-06-22
AR124123A1 (es) 2023-02-15
WO2022106665A1 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
JP7728822B2 (ja) キメラ抗原受容体及びｔ細胞受容体並びに使用方法
JP7834028B2 (ja) Ｉｌｔ結合剤及びその使用方法
JP7797614B2 (ja) Ｃｄ１２３結合性ポリペプチド及びその使用
RU2725811C1 (ru) Антитела против 4-1bb человека и их применение
US20220251232A1 (en) Novel anti-cd25 antibodies
JP6875295B2 (ja) Ｔｉｇｉｔ結合物質およびその使用法
TW202210514A (zh) 針對tigit的抗體
US20230057899A1 (en) Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
US20230139944A1 (en) Targeting alpha3beta1 integrin for treatment of cancer and other diseases
CN114040927A (zh) 结合cd33的多肽及其用途
US20240002521A1 (en) Anti-cd25 antibodies
WO2023020459A1 (zh) 靶向SIRPα的单克隆抗体及其用途
CN115768467A (zh) 用于治疗癌症和感染的针对NKp46的抗体及其构建体
CN116829588A (zh) 新型抗lilrb2抗体和衍生产物
KR20180030561A (ko) Nk 세포 살해 활성을 증대시키기 위한 방법 및 약학 조성물
KR20190117467A (ko) IFN-γ-유도성 조절 T 세포 전환가능 항암 (IRTCA) 항체 및 그의 용도
CN116917318A (zh) 抗cd25抗体
TW202202523A (zh) 抗-pd-1 抗體及用途的方法
WO2024163530A2 (en) Novel anti-ccr4 antibodies and derivative products
US20240382592A1 (en) Methods for the treatment of anaplastic large cell lymphoma
WO2023143478A1 (en) Novel anti-cd4 and anti-pd-l1 bispecific antibodies
CA3176246C (en) Antibodies to tigit
WO2023222886A1 (en) Antibody-cytokine fusion proteins
CN115698070A (zh) Cd5l结合抗体及其用途
HK1254148A1 (en) Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination